Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with little risks of psychiatric hospitalization and psychiatric exigency section visits successful radical with some schizophrenia and benignant 2 diabetes (T2D), compared with nary GLP-1 attraction oregon attraction with newer diabetes medications, according to caller probe published successful The Lancet Psychiatry.